

GeneExpression Systems, Inc. Presents:
Neuron to Synapse-2008 Meeting

On

'Neurobiology to Neurodegenerative Diseases & Therapeutics'
May 27 – 28, 2008

The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115, USA

Tel: 781-891-8181; Fax: 781-891-8234; E-mail: Genexpsys@expressgenes.com; www.expressgenes.com

AGENDA/SPEAKERS*
Day 1: Tuesday, May 27

8.00 A.M: **Registration Open: Coffee & breakfast**

9.00 – 9.15 AM **Chairman's Welcoming Note**
K. Appasani, PhD., MBA. GeneExpression Systems, Inc.

9.00 – 10.50 PM **Session I. Neurobiology of Alzheimer Disease**
Session Chair: Krishnarao Appasani

9.15 – 10.00 AM: **Keynote Lecture By**
Bradley T. Hyman, MD., PhD.
John B. Penney Jr Professor of Neurology & Director of Alzheimer Disease Res. Ctr.
Harvard Medical School, Massachusetts General Hospital, Charlestown MA, USA
Title: Molecular imaging and the pace of Alzheimer disease

10.00 – 10.25 AM: **Robert C. Green, M.D., M.P.H.**
Professor of Neurology, Genetics and Epidemiology &
Co-Director, Alzheimer's Disease Clinical & Research Program
Boston University, Schools of Medicine and Public Health, Boston, MA, USA
Title: **TBA**

10.25 – 10.50 AM: **Israel Schechter, M.D., Ph.D.**
Professor of Immunology
The Weizmann Institute of Science, Rehovot, Israel
Title: Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional b-secretase candidate(s)

10.50 – 11. 10 AM: **Refreshment Break (20 min)**

11.100 – 12.25 PM **Session II. Biology of Other Neurodegenerative Diseases**
Session Chair: Peter Lansbury

11.10 – 11.35 AM: **Peter T. Lansbury, Jr. PhD.**
Professor of Neurology, Brigham & Women's Hospital-Harvard Medical School &
Chief Scientific Officer and Chairman
Link Medicine Corporation, Cambridge, MA, USA
Title: New approaches to the treatment of neurodegenerative diseases

11.35 – 12.00 PM: **Ian Scott, PhD.**
Senior Director of Chemistry
Acucela, Inc., Seattle, WA, USA
Title: Visual Cycle Modulation - An Approach to the Treatment of Age-Related Macular Degeneration

12.00 – 12.25 PM: **Amar Thyagarajan, PhD.**
Postdoctoral Associate in the Lab of Dr. Alice Ting of Chemistry Dept.

Massachusetts Institute of Technology, Cambridge, MA, USA

Title: Novel protein labeling technologies to image protein interactions and trafficking at neuronal synapses

12.25 – 1.30 PM: Lunch Break (1 hr.) ON YOUR OWN

1.30 – 3.10 PM: Session III: Receptors & Channels: Part 1

Session Chair: Sha Mi

1.30 – 1.55 PM: John Lisman, PhD.

Professor of Biology at the Volen Center for Complex Systems
Brandeis University, Waltham, MA, USA

Title: The Molecular and Synaptic Basis of Memory

1.55 – 2.20 PM: Andreas Jeromin, PhD.

Manager of Methods Development
Allen Institute for Brain Science & University of Washington, Seattle, WA, USA

Title: Single-molecule tracking and total-internal reflectance microscopy to monitor the membrane dynamics and organization of Kv4.2 and high-throughput profiling of ion channel expression in human brain

2.20 – 2.45 PM: Ru-Rong Ji, PhD.

Associate Professor of Anesthesiology
Pain Research Center, Brigham & Women's Hospital, Boston, MA, USA

Title: Unraveling neuropathic pain mechanisms

2.45 – 3.10 PM: Ronald B. DeMattos, PhD.

Research Advisor in Neuroscience Division
Lilly Research Laboratories, Indianapolis, IN, USA

Title: TBA

3.10 – 3.40 PM Refreshment Break (30 min)

3.40 – 5.45 PM: Session IV: Receptors & Channels: Part 2

Session Chair: J. Thomas Megerian

3.40 – 4.05 PM: J. Thomas Megerian, MD, PhD.

Executive Director for Clinical Development
EPIX Pharmaceuticals, Inc., Lexington, MA, USA

Title: TBA

4.05 – 4.30 PM: Jesus "Tito" Gonzalez, Ph.D.

Senior Director of Biology
Vertex Pharmaceuticals, San Diego, CA, USA

Title: Accessing Voltage-gated Channels Drug Targets for Nervous System Disorders

4.30 – 4.55 PM: Grant A. Krafft, PhD.

Chairman and Chief Science Officer
Acumen Pharmaceuticals, Inc., South San Francisco, CA, USA

Title: ADDL-Mediated synaptic signaling causes AD memory deficits: New Therapeutic strategies to restore cognitive function

4.55 – 5.20 PM: Chris Mathes, Ph.D.

Vice-President & General Manager
Sophion Bioscience, Inc., North Brunswick, NJ, USA

Title: Diseases of Channels

5.20 – 5.45 PM: Speaker TBA.

Merck Research Labs

Title: TBA

5.45 PM: End of the day

Day 2: Wednesday, May 28

7:30 A.M: **Registration Open: Coffee & breakfast**

8.00 – 8.05 AM: **Opening of the Sessions**

8.00 – 9.45 PM: Session V: Neuronal Regeneration, Circuits & Synapse Formation

Session Chair: Ed Boyden

8.05 – 8.30 AM: **Sha Mi (Misha), PhD.**

Principal Investigator & Director of Neuro- Discovery Biology
Biogen Idec, Cambridge, MA, USA

Title: Lingo-1 and its role in CNS repair

8.30 – 8.55 AM: **Zhigang He, Ph.D.**

Associate Professor of Neurology
Children's Hospital, Boston, MA, USA

Title: Mechanisms of Axon regeneration

8.55 – 9.00 AM: **Announcement & Presentation of Neuron Innovator Award**

9.00 – 9.45 AM: **Joshua Sanes, PhD.**

Professor of Molecular and Cellular Biology
Paul J. Finnegan Family Director, Center for Brain Science
Harvard University, Cambridge, MA, USA

Title: Formation, maturation and maintenance of synapses

9.45 – 10.10 AM: **Ed Boyden, PhD.**

Benesse Career Development Professor & Assistant Professor
MIT Media Lab & Biological Engineering, Cambridge, MA, USA

Title: Optical Neural Control: Analyzing and Engineering Normal and Pathological Neuronal Circuit Dynamics

10.10 - 10.30 AM: **Coffee Break (20 min)**

10.30 – 12.15 PM: **Session VI: Neuronal Diseases & Therapeutic Strategies: Part 1**

Session Chair: Kenton Zavitz

10.30 – 10.55 AM: **Kenton H. Zavitz, Ph.D.**

Senior Director of Clinical Affairs
Myriad Pharmaceuticals, Inc., Salt Lake City, UT, USA

Title: Tarenflurbil (Flurizan™), a Selective A β 42-Lowering Agent, as a Potential Treatment for Alzheimer's Disease

10.55 – 11.20 AM: **Alberto Ascherio, MD., Dr.Ph.**

Associate Professor of Nutrition and Epidemiology
Harvard School of Public Health, Boston, MA, USA

Title: Role of epidemiology in neurodegeneration research: Lessons from Parkinson's

11.20– 11.45 PM: **Alistair Stewart, PhD.**

Director of Corporate Development
Allon Therapeutics Inc., Vancouver, BC, Canada

Title: Translation from research to clinical proof-of-concept: AL-108 for neurodegenerative diseases

11.45– 12. 10 PM: **Trine Veje Axelsen, MS.**

Industry PhD-student at the Aarhus University, Denmark &

Loke Diagnostics ApS, Risskov, Denmark
Title: Development of monoclonal antibodies against beta amyloid

12.10 – 1.30 PM Lunch Break (1 hr. 20 min) ON YOUR OWN

1.30 – 3.05 PM Session VII: Learning, Memory and Stem Cell Therapies for treating Epilepsy
Session Chair: Krishnarao Appasani

1.30 – 1.35 PM: Announcement & Presentation of Lifetime Achievement Award

1.35 – 2.15 PM: Leon N Cooper, PhD.

Nobel Laureate in Physics 1972

Thomas J. Watson, Sr. Professor of Science

Director of the Institute for Brain and Neural Systems

Brown University, Providence, RI, USA

Title: Towards a Cellular and Molecular Basis for Learning and Memory

2.15 – 2.40 PM: Toshiaki Nakashiba, PhD.

Research Scientist in the lab of Prof. Susumu Tonegawa

The Picower Institute of Learning and Memory

Massachusetts Institute of Technology, Cambridge, MA, USA

Title: Transgenic Inducible and reversible inhibition of synaptic transmission reveals role of CA3 output in hippocampal learning and memory

2.40 – 3.05 PM: Janice R. Naegele, PhD.

Professor and Chair of Biology

Wesleyan University, Middletown, CT, USA

Title: Stem Cell Therapies for Treating Temporal Lobe Epilepsy

3.05 – 3.30 PM: Coffee Break (20 min)

3.30 – 5.15 PM: Session VIII: Neuronal Diseases & Therapeutic Strategies: Part 2

Session Chair: TBA

3.30 – 3.55 PM: Speaker TBA

3.55 – 4.20 PM: Holly D. Soares, PhD.

Director in Translational Medicine

Pfizer Global Research and Development

TBA: The Use of Biomarkers in Clinical Development of Alzheimer's disease

4.20 – 4.45 PM: Dione Kobayashi, PhD.

Principal scientist

Rinat Labs, Pfizer, Inc., South San Francisco, CA, USA

Title: Inert C-terminal A β antibody efficacy in an Alzheimer's model

4.45 – 5.10 PM: Stephan Schilling, PhD.

Director of Enzymology

Probiodrug AG, Halle (Saale), Germany

Title: Pyroglutamated A β peptides-N-terminally blocked A β variants generated by glutam(in)yl cyclase

5.15 PM: CLOSING REMARKS BY THE CHAIRMAN

* Speaker names, titles and order may subject to change.

Font sizes of some of the presentations might be changed during the production of this proceeding. GES is not responsible for such changes.

Materials presented in this book/website should not be reproduced without the permission of GeneExpression Systems, Inc.

© GeneExpression Systems, Inc. 2008